# Amgen EVP of Operations Arleen Paulino Files Initial Beneficial Ownership Statement for 4,455 Shares

> Amgen EVP of Operations Arleen Paulino filed an initial beneficial ownership statement disclosing 4,455 directly owned common shares via EDGAR on November 20, 2026.

- Published: 2026-11-21T01:43:07+00:00
- Section: Leadership
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-21/amgen-paulino-beneficial-ownership-filing
- Source: [The future of trading](https://capital.com/en-int/news/amgen-files-initial-beneficial-ownership-statement-for-arleen-paulino-evp)

## Key takeaways

- Arleen Paulino, Amgen's Executive Vice President of Operations, disclosed 4,455 directly owned common shares in an initial beneficial ownership filing.
- Amgen published the filing through EDGAR on November 20, 2026, under reference ID 0000318154-26-000166.
- Amgen's leadership roster lists Robert A. Bradway as Chairman and Chief Executive Officer and Peter Griffith as Executive Vice President and Chief Financial Officer.

Amgen Executive Vice President of Operations Arleen Paulino disclosed 4,455 directly owned common shares in an initial beneficial ownership statement, [The future of trading](https://capital.com/en-int/news/amgen-files-initial-beneficial-ownership-statement-for-arleen-paulino-evp) reported. Amgen published the filing through EDGAR on November 20, 2026, under reference ID 0000318154-26-000166.

## Paulino's Filing and the Operations Role

The statement is an initial beneficial ownership filing, and it lists 4,455 common shares held directly by Paulino. The filing identifies Paulino by her title as Executive Vice President of Operations at [Amgen](https://akta.pro/company-profiles/0000459/amgen-inc).

Amgen submitted the original content behind the brief to the Securities and Exchange Commission through EDGAR, the agency's Electronic Data Gathering, Analysis, and Retrieval system. The brief carrying the disclosure was published on November 21, 2026.

Paulino's role sits outside the executive offices named in the company's leadership roster. That roster lists Robert A. Bradway as Chairman and Chief Executive Officer, James Bradner as Executive Vice President of Research and Development, Peter Griffith as Executive Vice President and Chief Financial Officer, and David M. Reese as Executive Vice President and Chief Technology Officer, according to akta.pro [company records](https://akta.pro/company-data).

## Amgen's Manufacturing and AI Partnerships

Company records show Amgen's operations footprint extending across several sites. Amgen opened a biomanufacturing plant in Central Ohio in February 2024, adding to manufacturing locations in Puerto Rico, Rhode Island, Singapore and Ireland, the same records show.

Amgen partnered with OpenAI in June 2026 on the GPT-Rosalind life sciences AI reasoning model, applying AI across drug discovery, biology and translational medicine workflows. Amgen is also piloting the FDA's real-time clinical trial monitoring program, streaming live clinical data into FDA review systems through an AI-powered cloud platform.

## Amgen's Recent Guidance and Regulatory News

Amgen raised its 2026 revenue and EPS guidance twice, citing growth from Repatha, UPLIZNA and IMDELLTRA offsetting a 45% decline in Prolia, 247wallst reported on November 17, 2026.

Amgen raised its 2026 quarterly dividend by 6% to $2.52, up 8.3% annually since fiscal 2020, TIKR reported on November 12, 2026. Q3 revenue rose 8% to $10.4 billion, and the company raised full-year guidance for the third time, according to the same report.

Amgen received an FDA warning letter for a Vectibix promotional video that downplayed serious side effects, Simply Wall St reported on November 11, 2026. The FDA ordered the video's removal and corrective actions.

## Companies in this story

- [Amgen Inc. company profile](https://akta.pro/company-profiles/0000459/amgen-inc) · website: https://www.amgen.com.sg

---
News for Agent · https://newsforagent.com/llms.txt
